Hyperthermia with Chemotherapy for Unresectable Gastric Cancer in a Patient with a Vagus Nerve Stimulator Implant: A Case Report.


Journal

The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566

Informations de publication

Date de publication:
17 Aug 2021
Historique:
entrez: 17 8 2021
pubmed: 18 8 2021
medline: 19 8 2021
Statut: epublish

Résumé

BACKGROUND Radiofrequency (RF) hyperthermia is commonly used as an adjunct to established treatment modalities such as chemotherapy and radiotherapy for the management of cancer patients. This case report aims to introduce the use of hyperthermia, in combination with chemotherapy, for the treatment of unresectable gastric cancer in a patient implanted with a vagus nerve stimulator (VNS). CASE REPORT A 55-year-old man with dermatomyositis, laryngeal squamous cell carcinoma in situ and double synchronous gastric cancer was found to have unresectable gastric disease during surgery despite neoadjuvant chemotherapy. Postoperatively, he received chemotherapy with RF hyperthermia. The patient had a VNS implant to treat epileptic seizures. VNS failure due to RF hyperthermia was an area of significant concern, and the procedures were completed with a full preparation to manage epileptic seizures in the event of its anticipated occurrence. Twenty-one thermotherapies were performed over 21 weeks. After 3 courses of S-1 chemotherapy (12 weeks) with RF hyperthermia without any adverse events, the regimen was changed to S-1+ CDDP combination chemotherapy (SP) and RF hyperthermia. The patient continued to receive treatment with a decrease in the size of the primary gastric tumors as well as lymph node metastases, without major adverse events, until he died due to disseminated disease. CONCLUSIONS We report the first case of unresectable gastric cancer with VNS implants in which chemo-hyperthermal therapy was safe and successful. This case report highlights the importance of providing a multidisciplinary treatment with appropriate measures for patients with intractable cancer who have received special treatments for underlying comorbidities.

Identifiants

pubmed: 34400601
pii: 931564
doi: 10.12659/AJCR.931564
pmc: PMC8380855
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e931564

Références

Cancer Med. 2015 Jun;4(6):834-43
pubmed: 25664976
J Huazhong Univ Sci Technolog Med Sci. 2013 Dec;33(6):870-876
pubmed: 24337851
Gastric Cancer. 2020 Jul;23(4):677-688
pubmed: 32036492
J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28
pubmed: 24366758
Int J Hyperthermia. 2019 Nov;36(sup1):4-9
pubmed: 31795827
R I Med J (2013). 2020 Apr 1;103(3):33-37
pubmed: 32236159
Int J Hyperthermia. 2016 Jun;32(4):455-63
pubmed: 27050781
Integr Cancer Ther. 2018 Jun;17(2):558-561
pubmed: 28745084
Am J Physiol. 1985 Jul;249(1 Pt 2):H133-40
pubmed: 4014479
Int J Hyperthermia. 2012;28(6):528-42
pubmed: 22690925
Lancet Oncol. 2002 Aug;3(8):487-97
pubmed: 12147435
Onco Targets Ther. 2020 Feb 26;13:1751-1756
pubmed: 32161470
Evid Based Complement Alternat Med. 2013;2013:672873
pubmed: 23662149
Cancer Res Treat. 2019 Jul;51(3):841-850
pubmed: 31048663
Eur J Radiol. 2011 Sep;79(3):343-6
pubmed: 20434862
Front Immunol. 2015 Nov 20;6:588
pubmed: 26635802
Cancer. 2011 Mar 15;117(6):1163-71
pubmed: 21381009
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510
pubmed: 31101534
Int J Hyperthermia. 2017 Feb;33(1):25-33
pubmed: 27411731
Semin Oncol. 2014 Dec;41(6):714-29
pubmed: 25499632
N Engl J Med. 1992 Feb 6;326(6):363-7
pubmed: 1729618
Gastric Cancer. 2018 Mar;21(2):315-323
pubmed: 28616743
Int J Hyperthermia. 2015;31(6):609-14
pubmed: 25975276
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
Am J Case Rep. 2020 Nov 03;21:e926647
pubmed: 33141812
Integr Cancer Ther. 2018 Dec;17(4):1297-1303
pubmed: 30193538
CA Cancer J Clin. 2009 Mar-Apr;59(2):73-98
pubmed: 19258446

Auteurs

Hirozumi Sawai (H)

Department of Surgery, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Shuhei Ueno (S)

Department of Surgery, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Yoshimi Yamaguchi (Y)

Radiological Technology, Department of Medical Technique, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Yuka Suzuki (Y)

Radiological Technology, Department of Medical Technique, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Akemi Murata (A)

Radiological Technology, Department of Medical Technique, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Enami Suganuma (E)

Radiological Technology, Department of Medical Technique, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Kazuya Yamamoto (K)

Radiological Technology, Department of Medical Technique, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Hiromasa Kuzuya (H)

Department of Surgery, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Shuji Koide (S)

Department of Surgery, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Masaaki Kurimoto (M)

Department of Surgery, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Takeshi Yanagi (T)

Department of Proton, Narita Memorial Proton Center, Toyohashi, Aichi, Japan.

Hajime Koide (H)

Department of Surgery, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Atsushi Kamiya (A)

Department of Surgery, Narita Memorial Hospital, Toyohashi, Aichi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH